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Abstract
Purpose: To evaluate whether response assessment of newly diagnosed glioblastoma at 3 months using 11C-methionine-positron
emission tomography (MET-PET) is better associated with patient outcome compared with baseline MET-PET or anatomic magnetic
resonance imaging alone.
Methods and Materials: Patients included were participants in a phase I/II trial of dose-escalated chemoradiation based on anatomic
magnetic resonance imaging. Automated segmentation of metabolic tumor volume (MTV) was performed at a threshold of 1.5 times
mean cerebellar uptake. Progression-free (PFS) and overall survival were estimated with the Kaplan-Meier method and compared with
log-rank tests. Multivariate analysis for PFS and overall survival was performed using Cox proportional hazards, and spatial overlap
between imaging and recurrence volumes were analyzed.
Results: Among 37 patients, 15 had gross total resection, of whom 10 (67%) had residual MTV, 16 subtotal resection, and 6 biopsy
alone. Median radiation therapy dose was 75 Gy (range, 66-81). Median baseline T1 Gd-enhanced tumor volume (GTV-Gd) was
38.0 cm3 (range, 8.0-81.5). Median pre-CRT MTV was 4.9 cm3 (range, 0-43.8). Among 25 patients with 3-month MET-PET, MTV was
only 2.4 cm3 (range, 0.004-18.0) in patients with uptake. Patients with MTV Z 0 cm3 at 3 months had superior PFS (18.2 vs
10.1 months, P Z .03). On multivariate analysis, larger 3-month MTV (hazard ratio [HR] 2.4, 95% confidence interval [CI], 1.4-
4.3, P Z .03), persistent MET-PET subvolume (overlap of pre-CRT and 3 month MTV; HR 2.0, 95% CI, 1.2-3.4, P Z .06), and
increase in MTV (HR 1.8, 95% CI, 1.1-3.1, P Z .09) were the only imaging factors significant for worse PFS. GTV-Gd at
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recurrence encompassed 97% of the persistent MET-PET subvolume (interquartile range 72%-100%), versus 71% (interquartile range
39%-93%) of baseline MTV, 54% of baseline GTV-Gd (18%-87%), and 78% of 3-month MTV (47%-95%).
Conclusions: The majority of patients with apparent gross total resection of glioblastoma have measurable postoperative MTV. Total
and persisting MTV 3 months post-CRT were significant predictors of PFS, and persistent MET-PET subvolume was the strongest
predictor for localizing tumor recurrence.
 2019 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Glioblastoma (GBM) is traditionally treated by
maximal safe resection followed by chemoradiation
(CRT); however, overall survival remains poor despite
decades of research.1,2 Radiation therapy is a backbone of
treatment because these tumors are always incompletely
surgically removed. Typically, radiation planning relies
on T1-weighted gadolinium enhanced (T1-Gd) and T2/
fluid-attenuated inversion recovery (FLAIR) magnetic
resonance imaging (MRI) to define tumor treatment vol-
ume.3,4 However, the T1-Gd volume does not fully
encompass the tumor volume as some infiltrative portions
of tumor are nonenhancing.5 This has led to the investi-
gation of biologically based imaging techniques, such as
advanced MRI and radiolabeled positron emission to-
mography (PET), which have been shown to identify
areas of tumor not identified with traditional MRI.6-13
Glucose-labeled radiotracers like 2-deoxy-2-(18F)flu-
oro-D-glucose are less useful in gliomas owing to insuf-
ficient distinction between tumor and the background
cortex and the inability to distinguish from benign sources
of inflammation.14,15 In contrast, amino acid tracers have
superior ability to diagnose, grade, and delineate extent of
glioma; guide surgical and radiation treatment planning;
and assess response.14 In particular (11C-methionine)-
positron emission tomography (MET-PET), the most
well-studied amino acid radiotracer in malignant brain
tumors, has been found to have a high detection rate with
improved tumor delineation based on histopathologic
confirmation.16 MET-PET uptake is increased in GBM
owing to increased expression of L-amino acid transporter
in tumor cells compared with normal brain tissue and
increased metabolism of methionine which results in
higher avidity for 11C-methionine in tumor.17 In contrast,
T1-gadolinium enhanced MRI, the standard imaging for
GBM diagnosis and therapeutic intervention, relies upon
nonspecific increased permeability of the blood-brain
barrier, which may be present in the absence of tumor
or may be absent in regions of infiltrative disease.18-20
Both standardized uptake value metrics (the ratio of in-
tensity in tumor compared with normal brain tissue) as
well as metabolic tumor volume (MTV) may be quanti-
tated from amino acid PET scans including 11C-MET
PET. Direct comparison between MTV and standardized
uptake value suggests that the MTV may be more prog-
nostic for overall survival because it better characterizes
the whole tumor volume rather than the evaluation of a
single voxel with greater intensity.21,22
Recognizing the prognostic limitations of anatomicMRI
and the previously identified value of MTV, we sought to
evaluate the prognostic value of MTV identified by MET-
PET before and after chemoradiation, andwhether 3-month
response assessment was better associated with patient
outcome compared with baseline or anatomic MRI alone.
Additionally, spatial correlation between MTV and
persistent MTVwith recurrent tumor volume was explored
to determine whether biologically significant tumor sub-
volumes could be identified that may serve as potential
radiation therapy targets in future studies.
Methods
Study patients and data collection
We performed an institutional review boardeapproved
retrospective analysis of patients with newly diagnosed
histologically confirmed supratentorial World Health Or-
ganization grade IV gliomas who were treated on a phase
I/II clinical trial evaluating dose-escalated radiation ther-
apy (RT) based on anatomic MRI alone from 2003 to
2007.23 After surgery but before radiation treatment,
baseline anatomic MRI, including T1-Gd and T2/FLAIR
images and MET-PET scans were obtained. A subset of
patients underwent MET-PET imaging 3 months post-
chemoradiation. Clinical and pathologic information was
obtained from the medical record. The extent of resection
was defined based on the postoperative imaging and
multidisciplinary assessment.
Radiation treatment
All patients were treated on a prospective dose escala-
tion trial using standard anatomic MRI that has previously
been published.23 Residual T1-weighted gadolinium
enhanced tumor or resection cavity (after gross total
resection) was defined on the T1-Gd MRI (GTV-Gd).
54 S. Miller et al Advances in Radiation Oncology: JanuaryeFebruary 2020
Downloaded for Anonymous User (n/a) at Washington University in Saint Louis Bernard Becker Medical Library from ClinicalKey.com by Elsevier on February 10, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Clinical target volume was defined as GTV-Gd expanded
by 1.5 cm delimited by anatomic boundaries. Two planning
target volumes (PTV) were defined: PTV1 was clinical
target volume plus 0.5 cmwhichwas planned to 60Gy in 30
fractions. PTV2 was GTV-Gd plus 0.5 cm planned using
simultaneous integrated boost to an assigned dose level (66-
81 Gy in 30 fractions) via forward- or inverse-planned in-
tensity modulated radiation therapy. Per protocol, at least
99.5% of the PTV was encompassed by the 95% pre-
scription isodose surface (IDS).
MET-PET imaging
Baseline and 3-month follow-up MET-PET scans were
obtained on a Siemens ECAT EXACT HR plus whole-
body tomography with axial resolution 4.1 mm FWHM in
the center of the field of view.24 Owing to the short half-
life of 11C-methionine, a cyclotron was required on site. A
6-minute long (approximately 1.5 million counts) trans-
mission scan was obtained using 3 Ge-68 rod sources
before intravenous injections of approximately 740 MBq
of MET. Ten to 30 minutes later emissions scan image
data was obtained in 3-dimensional mode, which was
summed into a single frame and analyzed. An all-pass
filter reconstructed iteratively emission data corrected
for attenuation, scatter, and random coincidences with 4
iterations and 16 subsets (128  128 pixel matrix).
Image registration
The pre-RT treatment planning (computed tomogra-
phy) CT, FLAIR MRI, and MET-PET images were cor-
egistered with the T1-Gd MRI using an in-house
functional imaging analysis tool (imFIAT).25 The 95%
IDS was generated from the planned composite dose
distribution and aligned with the T1-Gd MRI through
coregistration with CT. The T1-Gd recurrence MRI was
coregistered to the baseline T1-Gd MRI. All image
registrations were done using rigid body transformation
and mutual information. Nonrigid transformation was
necessary for one patient owing to cavity change over
time. Image registration was confirmed by visual i-
nspection, split-screen, scrolling slice by slice, viewing in
different planes, and by comparing contour overlays.
Metabolic tumor volume delineation
For MET-PET scans at baseline and 3 months, auto-
mated segmentation of MTV was performed using
imFIAT and a threshold of 1.5 times mean cerebellar
uptake as previously described.13 Uptake in normal tissue
(ie, lacrimal and pituitary glands) was manually excluded
to create the MTV.26 Persistent MTV at 3 months was
defined as the subvolume of overlap between the 3-month
MTV and the pre-CRT (baseline) MTV.
Follow-up and patterns of failure analysis
Progression was typically defined by multidisciplinary
determination as radiographic evidence of Gd-enhanced
progression and clinical findings. The pattern of failure
tumor volume (TVPOF) was defined based on the T1-Gd
MRI obtained at time of progression in all but 2 cases
who underwent a contrast CT instead of MRI. One of
these patients had analyzable imaging data and was
included in the pattern of failure analysis, whereas the
other had imaging data that was unable to be used due to
errors in the image file.
Statistical analysis
Progression-free survival (PFS) was defined as the
interval from diagnosis to progression or death. Overall
survival was defined as the interval from diagnosis to
death of any cause or date of last follow-up for alive
patients, calculated using Kaplan-Meier methods. Com-
parison of PFS and OS outcomes for patients with and
without detectable MTV at 3 months was performed using
log-rank test. Univariate and multivariate Cox propor-
tional hazard models were used to identify factors asso-
ciated with PFS and OS. Clinical factors included were
age (continuous), sex, Karnofsky Performance Status
(KPS; 90 vs < 90), extent of surgery (gross total
resection [GTR] vs subtotal resection [STR] vs biopsy),
O6-methylguanine-DNA methyltransferase (MGMT)
promoter methylation status, and radiation dose (contin-
uous). Imaging variables tested included GTV-Gd, GTV-
FLAIR, MTV at baseline, and MTV at 3 months. Imaging
subvolumes included persistent MTV at 3 months, MTV
inside and outside the 95% IDS, and MTV outside GTV-
FLAIR. Progression related features were included as
time dependent covariates in the OS models. In the
multivariate analysis, clinical covariates that were sig-
nificant in the univariate analysis were included (KPS,
age, and extent of resection) and one imaging covariate
was added at a time in a step-wise fashion to create 11
multivariate models with 4 covariates each. For multiple
testing of imaging covariates, the Benjamini-Hochberg
method was used for false discovery rate (FDR) control
with the FDR control rate set to 10%.27 For continuous
covariates, the reported hazard ratio (HR) was per 1
standard deviation increase to allow for comparison of the
magnitude of HRs between different imaging metrics.
Results
Baseline patient and imaging characteristics
The 37 patients who participated on a phase I/II dose
escalation study were included in this analysis. The
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median age was 53 years (range, 20-75), and 49% of
patients were male.23 Fifteen had GTR, 16 STR, and 6
biopsy alone (Table 1). Median time from surgery until
baseline pre-RT MRI and MET-PET was 20 days (range,
1-43) and 21 days (range, 6-40), respectively. Median
prescribed RT dose was 75 Gy (range, 66-81). All pa-
tients received concurrent temozolomide (TMZ) and 32
patients (86%) received adjuvant TMZ; 5 did not receive
adjuvant TMZ owing to clinical deterioration or death.
Among the subset of patients in whom MGMT methyl-
ation status was available, 6 of 10 had MGMT promoter
methylation.
The median postoperative GTV-Gd was 38.0 cm3
(range, 8.0-81.5) and the median GTV-FLAIR was
73.2 cm3 (range, 9.7-206.2; Table 2). In comparison, the
median postoperative MTV was 4.9 cm3 (range, 0-43.8).
Ten of the 15 (67%) patients with apparent GTR had
residual MTV. The median enhancing component of the
MTV was 4.2 cm3 (range, 0-32.8) with a median of 77%
of the MTV demonstrating enhancement (range, 2%-
100%). The median nonenhancing component was
1.2 cm3 (range, 0-24.5), and the median MTV outside of
GTV-FLAIR was 0.2 cm3 (range, 0-4.7); 8 of 37 had
1 cm3 of MTV outside of GTV-FLAIR. Therefore, 3
patients had 1 cm3 MTV extending outside of the 95%
IDS, because GTV-FLAIR was not specifically targeted.
Changes in MTV 3 months post chemoradiation
Twenty-five of the 37 patients underwent MET-PET
imaging approximately 3 months from completion of
chemoradiation. In contrast to the baseline MTV
(4.9 cm3), the median MTV at 3 months among patients
with uptake was only 2.4 cm3 (range, 0.004-18.0), and 9
of 25 patients had no uptake at 3 months. Only one patient
had an increase in MTV and experienced early failure
<6 months posttreatment, whereas the remaining patients
had a reduction in absolute volume in MTV. Six of 22
patients (27%) with uptake pre-CRT had no residual
MTV at 3 months (Fig 1). The median reduction in MTV
from baseline was 2.7 cm3 (range, e0.1 to 41.4). At
3 months, the median persistent MET-PET subvolume
(overlap between the baseline and 3-month MET-PET)
was 1.5 cm3 (range, 0-10.9), and 9 of 25 patients had
1 cm3 of overlap.
Survival outcomes
Among all patients, median PFS was 9.5 months
(95% CI, 7.2-17.9) and median OS was 20.4 months
(95% CI, 15.6-36.8). The subset of patients with
MTV Z 0 cm3 at 3 months had superior PFS: 18.2 (95%
CI, 9.5-NA) versus 10.1 months (95% CI, 6.8-17.9;
P Z .03, Fig 2). Results of the univariate analysis for
PFS and OS are shown in Table 3. On multivariate
analysis (Table 4), worse KPS (HR 6.0, 95% CI 1.5-
23.8, P Z .01) and biopsy compared with GTR (HR 5.1,
95% CI 1.7-15.3, P < .01) were associated with worse
PFS. The only imaging factors significantly associated
with worse PFS were larger 3-month MTV (HR 2.4,
95% CI, 1.4-4.3, P < .01, P value after FDR 0.03),
Table 1 Patient, tumor, and treatment characteristics















Received adjuvant TMZ 32 (86)
Surgery type
Biopsy 6 (16)
Subtotal resection 16 (43)




Abbreviations: KPS Z Karnofsky Performance Status;
MGMT Z O6-methylguanine-DNA methyltransferase; TMZ,
temozolomide.
* Ten patients with available data.
Table 2 Characteristics of anatomic and metabolic imag-
ing volumes





Enhancing MTV 4.2 (0-32.8)
Nonenhancing MTV 1.2 (0-24.5)
MTV outside 95% IDS 0 (0-3.6)
3 mo
MTV at 3 mo 0.1 (0-18.0)
Change in MTV from baseline e2.7 (e41.4-0.1)
Persistent MTV subvolume 1.5 (0.0-10.9)
Abbreviations: IDS Z isodose surface; GTV-FLAIR Z volume of
fluid-attenuated inversion recovery intensity; GTV-
Gd Z gadolinium-enhanced gross tumor volume;
MTV Z metabolic tumor volume.
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persistent MET-PET subvolume (HR 2.0, 95% CI, 1.2-
3.4, P Z .01, P value after FDR 0.06), and an increase
in MTV from baseline (HR 1.8, 95% CI, 1.1-3.1,
P Z .02, P value after FDR 0.09). For OS, only KPS
(HR 15.6, 95% CI, 4.0-62.5, P < .01), age (HR 1.5,
95% CI, 1.0-2.2 P Z .05), and biopsy versus GTR (HR
3.3, 95% CI, 1.2-9.3, P Z .03) were significant
(Table 4).
Pattern of failure analysis
Thirty-four of 37 patients had documented progression
of disease. The median TVPOF was 28.3 cm
3 (range,
1.1-109.6). Across patients, the median GTV-Gd at
recurrence that encompassed the persistent MET-PET
subvolume was 97% (interquartile range 72%-100%),
compared with 71% (interquartile range 39%-93%) of the
baseline MTV, 54% of the baseline GTV-Gd (18%-87%),
and 78% of the 3-month MTV (47%-95%).
Discussion
In our study we found that despite apparent gross
total resection, the majority of patients had residual
MTV detected by MET-PET before chemoradiation.
However, neither MTV nor GTV-Gd before chemo-
radiation were associated with PFS or OS when ac-
counting for 3-month metabolic response. In contrast,
the presence of MTV 3 months post-CRT was signifi-
cantly associated with worse PFS and demonstrated a
spatial relationship to eventual progression. These find-
ings suggest that 3-month metabolic response assess-
ment may be used as a biomarker for prognostication
and early treatment decision making and may signify
Figure 1 Anatomic and metabolic tumor volumes (MTV) before and after chemoradiation in relation to recurrence. Patient 01 had a
subtotal resection with residual MTV extending anteromedially beyond the surgical cavity, with a complete metabolic response 3 months
post chemoradiation. He experienced delayed progressed at 19 months. Patient 02 underwent subtotal resection and demonstrated residual
MTV along the medial cavity that persisted 3 months post-chemoradiation, with subsequent early recurrence at 9 months. Patient 03
underwent gross total resection, yet had residual MTV that reduced in volume at 3 months. He experienced distant recurrence remote from
the original resection bed andMTV at 18months. RedZ enhancing gross tumor volume and surgical cavity (GTV-Gd); blueZMTV pre-
CRT; cyan Z MTV at 3 months; green Z 95% isodose surface; purple Z enhancing tumor recurrence volume.
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regions of treatment resistance that eventually repopulate
tumor recurrence. If these treatment-resistant sub-
volumes could be identified before treatment, they may
serve as potential targets for intensified local therapy
with surgery or radiation.
Response assessment after treatment of GBM stan-
dardly relies upon anatomic MRI.28 However, the use-
fulness of anatomic MRI several months after CRT is
known to be limited owing to difficulty in distinguishing
between tumor and other processes that disrupt the blood-
brain barrier such as medication effects, variation in im-
aging technique, treatment-related inflammation, seizures,
and postsurgical changes.29 As a result, advanced MRI
and PET imaging have been investigated as techniques for
response assessment.14 One study found that a decrease in
O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET PET)
maximum and mean tumor-to-brain ratio from pre-CRT
to 7 to 10 days after completion of CRT was associated
with improved PFS and OS.30 In the same study, reduc-
tion of 18F-FET uptake at 6 to 8 weeks after completion of
CRT was associated with improved PFS and trended to-
ward improved OS. Post-CRT GTV-Gd based on
anatomic T1-Gd MRI was not associated with PFS or OS
in this study. Response assessment using amino acid
tracers has also been studied after treatment with anti-
angiogenic therapies (bevacizumab) and alkylating
chemotherapy.31-35 Decreased uptake of 3,4-dihydroxy-6-
[(18)F]-fluoro-l-phenylalanine ((18)F-FDOPA), 18F-FET,
and MET-PET after chemotherapy in patients with
recurrent GBM have been shown to be associated with
improved survival.
Response assessment early during CRT using
advanced MRI techniques, such as parametric response
maps based on quantitative markers like relative cerebral
blood volume and apparent diffusion coefficient, in
addition to reduction in fractional high-cerebral blood
volume tumor volume have been associated with overall
survival.36-40 The relationship between these advanced
MRI techniques and various types of amino acid PET
imaging has not been well-characterized, and studies are
needed to evaluate whether these advanced imaging mo-
dalities are complementary in their characterization of
tumor biology and prognosis, and whether the combina-
tion of multiple imaging approaches may more optimally
characterize tumor heterogeneity and potentially guide
treatment.41
In our study, neither baseline MTV nor baseline GTV-
Gd was significant for PFS or OS. A previous study
looking at pretreatment MET-PET scans found MTV was
associated with OS on multivariate analysis and GTV-Gd
was not.42 Another study of 18 patients with newly
diagnosed GBM found preoperative MTV to be the only
significant factor associated with PFS on multivariate
analysis.43 No postoperative MTV was obtained to verify
extent of resection. Although we did not find baseline
MTV to be significantly associated with PFS, our imaging
timepoints included postoperative pre-CRT MET-PET
and post-CRT imaging, which provides a true metabolic
response assessment of the postoperative residual MTV
after CRT.
A prior study demonstrated that MTV outside of the
95% IDS was associated with noncentral tumor recur-
rence.13 In our present study, we found that baseline
MTV was not prognostic for PFS when accounting for
3-month metabolic response, but did find a spatial asso-
ciation between eventual tumor recurrence and MTV
persisting from baseline to 3 months post-CRT. Taken
together, these results suggest that successful
Figure 2 Progression free (PFS) and overall survival (OS) Kaplan-Meier curves of patients with. and without metabolic tumor volume
(MTV) at 3 months demonstrating significantly improved PFS and a trend toward improved OS in patients without MTV at 3 months
post chemoradiation.
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identification of these treatment-resistant subregions
before CRT may enable a dose-intensified approach that
could alter patterns of failure and prolong time to pro-
gression.44 Although the number of patients with
persistent MTV was small, persistent MTV was more
likely to be encompassed in the TVPOF than any other
imaging subvolume. Additionally, MTV at baseline and
at 3 months was more likely to be encompassed by
Table 3 Univariate Cox proportional hazards model of progression free survival and overall survival
OS PFS
Covariates*.y HR 95% CI P valuez HR 95% CI P valuez
Age 1.5 1.0-2.1 .04 1.0 0.7-1.5 .79
Male sex (vs female) 1.2 0.6-2.4 .60 1.6 0.8-3.1 .20
KPS (vs KPS 90) 14.5 3.8-55.6 .000 0.2 0.1-0.8 .03
STR (vs GTR) 0.9 0.4-1.9 .74 1.4 0.7-3.0 .34
Biopsy (vs GTR) 2.1 0.8-5.5 .14 4.3 1.5-12.5 .01
RT dose 0.9 0.6-1.2 .44 0.9 0.6-1.3 .70
MGMT methylated (vs unmethylated) 0.2 0.0-1.2 .07 0.3 0.1-1.3 .11
Gd-enhancing GTV 1.1 0.8-1.6 .95 1.4 0.9-2.0 .17
FLAIR-GTV 1.1 0.8-1.5 .95 1.4 1.0-2.0 .09
Baseline MTV 1.3 0.9-1.8 .90 1.6 1.2-2.3 .02
Baseline enhancing MTV 1.2 0.9-1.8 .90 1.6 1.1-2.2 .03
Baseline nonenhancing MTV 1.0 0.8-1.4 .95 1.2 0.8-1.6 .42
Baseline MTV outside FLAIR 1.2 0.8-1.8 .93 1.1 0.8-1.6 .57
Baseline MTV outside 95% IDS 1.0 0.7-1.3 .95 1.4 1.0-1.9 .10
Baseline MTV inside 95% IDS 1.3 0.9-1.8 .90 1.6 1.2-2.2 .02
3-month MTV 1.0 0.6-1.5 .95 1.8 1.1-2.7 .03
Persistent MTV subvolume at 3 months 1.0 0.6-1.6 .95 1.6 1.1-2.6 .07
Change in MTV from baseline 1.0 0.7-1.6 .95 1.3 0.9-2.0 .20
Abbreviations: CI Z confidence interval; FLAIR Z fluid attenuated inversion recovery; Gd Z gadolinium; GTR Z gross total resection;
GTV Z gross tumor volume; HR Z hazard ratio; IDS Z isodose surface; KPS Z Karnofsky Performance Status; MGMT Z O6-methylguanine-
DNA methyltransferase; MTV Z metabolic tumor volume; OS Z overall survival; RT Z radiation therapy; STR Z subtotal resection.
* For continuous covariates, HR is per 1 SD.
y HR for imaging covariates are per 10 cm3.
z For multiple testing, Benjamini-Hochberg method was used for false discovery rate control with the false discovery rate control rate set to 10%.
Table 4 Multivariate Cox proportional hazards model of progression free survival and overall survival
OS* PFS*
Covariatesy HR 95% CI P valuez HR 95% CI P valuez
KPS (vs KPS 90) 15.6 4.0-62.5 .000 6.0 1.5-23.8 .01
Age 1.5 1.0-2.2 .05 1.0 0.7-1.4 .88
STR (vs GTR) 1.2 0.5-2.6 .73 1.6 0.7-3.4 .26
Biopsy (vs GTR) 3.3 1.2-9.3 .03 5.1 1.7-15.3 .004
Gd-enhancing GTV 1.3 0.8-2.0 .91 1.2 0.8-2.1 .45
FLAIR-GTV 1.0 0.7-1.5 .98 1.3 0.9-2.0 .28
MTV pre-CRT 1.2 0.7-2.2 .91 1.6 0.8-3.0 .28
Baseline enhancing MTV 1.4 0.8-2.5 .91 1.4 0.8-2.5 .29
Baseline nonenhancing MTV 0.9 0.6-1.4 .91 1.0 0.7-1.5 .98
Baseline MTV outside FLAIR 1.1 0.6-1.8 .95 0.7 0.4-1.2 .28
Baseline MTV outside 95% IDS 1.0 0.7-1.4 .95 1.4 0.9-2.0 .26
Baseline MTV inside 95% IDS 1.2 0.7-2.3 .91 1.5 0.8-2.9 .29
MTV 3 month 1.3 0.8-2.4 .91 2.4 1.4-4.3 .03
Persistent MET-PET subvolume 1.3 0.7-2.4 .91 2.0 1.2-3.4 .06
Change in MTV from baseline 1.1 0.7-1.7 .95 1.8 1.1-3.1 .09
Abbreviations: CI Z confidence interval; FLAIR Z Fluid attenuated inversion recovery; Gd Z gadolinium; GTR Z gross total resection;
GTV Z gross tumor volume; HR Z hazard ratio; IDS Z isodose surface; KPS Z Karnofsky Performance Status; MGMT Z O6-methylguanine-
DNA methyltransferase; MTV Z metabolic tumor volume; OS Z overall survival; RT Z radiation therapy; STR Z subtotal resection.
* 11 models included with 4 covariates per model (age, KPS, extent of resection and imaging variable).
y For continuous covariates, HR is per 1 SD.
z For multiple testing, Benjamini-Hochberg method was used for false discovery rate (FDR) control with the FDR control rate set to 10%.
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TVPOF than the GTV-Gd, suggesting MTV can help
identify the volumes of tumor most likely progress.
However, the spatial analysis is limited because the MTV
volumes were much smaller than the GTV-Gd, which
would make it more likely to be encompassed by the
TVPOF. Moreover, the comparison of MTV with TVPOF
is limited as it presumes TVPOF defined on the T1-Gd
MRI accurately describes the recurrence volume. T1-Gd
MR imaging is the standard modality to assess tumor
response and disease status for GBM, but is nonspecific
and may not fully depict tumor extent posttreatment, or
readily distinguish between treatment effect and tumor
progression.28 The spatial analysis is hypothesis gener-
ating as it seems to suggest a relationship between the
MTV and eventual recurrence. This persistent MTV
identifies a distinct tumor subvolume potentially at
highest risk of recurrence compared with the remainder of
the MTV or anatomic imaging defined tumor volumes.
An aim of future studies would be to identify this treat-
ment resistant tumor subvolume before surgery or radia-
tion. One possible approach could be to correlate MTV
with advanced MRI techniques like perfusion and high b-
value diffusion weighted imaging. This is one of the
goals of an ongoing phase II clinical trial at our
institution.45
We did not observe a relationship between metabolic
imaging at baseline or 3 months and overall survival. This
could be due to limited patient numbers or collinearity
with extent of resection. Another limitation of our study is
a lack of molecular markers like MGMT promoter
methylation and IDH mutation status due to the era of
treatment. It would be interesting to note if MGMT
methylation was associated with MTV response as it has
been associated with change in standardized uptake.46
Conclusions
The majority of patients with apparent GTR of newly
diagnosed GBM have measurable postoperative MTV,
and total and persisting MTV volumes 3 months post-
CRT were the only imaging predictors of PFS in our
study. In particular, the persistent MET-PET subvolume
is the strongest predictor for localizing tumor recurrence,
and additional advanced imaging strategies should be
investigated to identify whether these highest-risk tumor
subregions can be identified before and during treatment
for adaptive radiation therapy strategies and prognosti-
cation during and after CRT.
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